The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
2013 · Scientific Reports · 119 citations
https://doi.org/10.1038/srep02469
E
Elisabet Cuyàs
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
125
Papers
4.3K
Citations
39
h-index
90
i10-index
Elisabet Cuyàs is an academic researcher from Institut Català d'Oncologia. The author has contributed to research in topics: Cancer, Hypoxia, and Metabolism & Epigenetics and DNA Methylation & Metabolism, Diabetes, and Cancer. The author has an h-index of 39, co-authored 107 publications.
ORCID: 0000-0001-5353-440XPapers by this author
worksChemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells
2014 · Oncotarget · 114 citations
https://doi.org/10.18632/oncotarget.2059
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
2013 · Scientific Reports · 75 citations
https://doi.org/10.1038/srep02459
The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer
2021 · Nature Communications · 40 citations
https://doi.org/10.1038/s41467-021-22101-7
Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
2015 · Oncotarget · 36 citations
https://doi.org/10.18632/oncotarget.6094
Metformin inhibits <i>RANKL</i> and sensitizes cancer stem cells to denosumab
2017 · Cell Cycle · 21 citations
https://doi.org/10.1080/15384101.2017.1310353
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat